• Futura Medical marks pivotal year with first meaningful revenue from Eroxon sales

    07 February 2024

  • Futura Medical continues global expansion with Latin America announcement

    07 November 2023

  • Proactive Investor Video

    September 2023

  • Futura Medical PLC - Interim Results 2023

    September 2023

  • Fireside Chat with James Barder, CEO of Futura Medical

    July 2023

  • Futura Medical "absolutely delighted" with US commercialisation agreement

    18 July 2023

  • Futura Medical in discussions with US partners after gaining FDA approval

    June 2023

  • Futura Medical debuts Eroxon in UK and says "more launches coming"

    April 2023

  • Futura Medical expects FDA approval for topical ED treatment during Q2

    March 2023

  • Futura Medical "on track" for launch in H1 2023

    December 2022

  • Fireside chat - Dr Sidney Glina & Dr Wayne Hellstrom

    13 December 2022

  • Futura Medical cheers a "very productive six months, delivering on strategic objectives"

    13 September 2022

  • Futura Medical hails positive phase III results as it prepares for US FDA sign-off for ED gel

    31 August 2022

    Futura Medical hails positive phase III results as it prepares for US FDA sign-off for ED gel

  • Futura Medical delighted with Cooper Health deal for MED3000

    24 May 2022

    Futura Medical delighted with Cooper Health deal for MED3000

  • Futura Medical PLC "in a good place" as it moves towards launch of MED3000

    26 April 2022

    Futura Medical PLC "in a good place" as it moves towards launch of MED3000

  • Futura Medical signs South Korean licensing deal for erectile dysfunction gel MED3000

    23 March 2022

    Futura Medical signs South Korean licensing deal for erectile dysfunction gel MED3000

  • Futura Medical PLC reaches licensing deal for erectile dysfunction gel in Brazil and Mexico

    31 August 2021

    Futura Medical PLC reaches licensing deal for erectile dysfunction gel in Brazil and Mexico

  • Futura Medical’s CEO discusses £12m fundraising for MED3000

    17 May 2021

    Futura Medical’s CEO discusses £12m fundraising for MED3000

  • Futura Medical mark 'very busy year' with three landmark steps for erectile dysfunction gel MED3000

    14 April 2021

    Proactive Investor interview with James Barder

  • Futura Medical 'at final administrative stages of getting approval' for MED3000 in Europe

    19 March 2021

    Proactive Interview with Ken James Futura Medical 'at final administrative stages of getting approval' for MED3000 in Europe

  • Futura Medical Announces Investment and Joint Collaboration to Commercialise MED3000 in China and South East Asia

    04 March 2021

    Futura Medical Announces Investment and Joint Collaboration to Commercialise MED3000 in China and South East Asia

  • Futura Medical announce regulatory and commercial progress on erectile disfunction gel

    22 October 2020

    James Barder Interview with Proactive Investor

  • Futura Medical gets set to begin formal approval steps for erectile dysfunction drug

    16 September 2020

    James Barder talks to Proactive Investor

  • Futura Medical assessing commercialisation options for CBD100

    03 August 2020

    James Barder interview with Proactive Investor

  • Futura Medical's Ken James updates on EU and US regulatory progress for MED3000

    13 July 2020

    Ken James interview with Proactive Investor

  • Regulatory submissions for MED3000 remain on track

    26 June 2020

    James Barder, Chief Executive interview with Proactive Investor’s Andrew Scott

  • Full Year Results for the year ended 31 December 2019

    01 April 2020

    James Barder, Chief Executive interview with Proactive Investor’s Andrew Scott

  • Interview with Executive Director and Head of R&D - EU regulatory update and analysis of FM57

    01 January 2020

    Ken James speaks to Proactive Investor’s Andrew Scott following positive initial discussions with EU regulators after an extensive internal evaluation of the clinical data from the Phase 3 study (“FM57”).

  • Interview with Executive Director and Head of R&D - Phase III Results

    02 December 2019

    Ken James speaks to Proactive London's Andrew Scott following the read-out from the phase III clinical trial of its erectile dysfunction gel.

  • Fireside chat - Ken James & Dr Wayne Hellstrom

    12 November 2019

    Fireside chat with Ken James & Dr Wayne Hellstrom

  • Interview of CEO – Interims

    02 September 2019

    James Barder caught up with Proactive London's Andrew Scott to talk through the company's interim results.

  • Introduction to Futura

    James Barder introduces Futura and its lead product MED2005

  • Fireside Chat

    01 February 2019

    Fireside chat with Professor David Ralph and Ken James

  • Milestone for Futura Medical

    Interview of Ken James, Head of R&D, by Proactive Investors in which he discusses milestone for Futura Medical

  • On track with Phase 3 trial

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses their Phase 3 trial

  • New safety data on lead treatment

    Interview of Ken James, Head of R&D, by Proactive Investors in which he discusses new safety data on lead treatment

  • Futura Medical doses first patient in Phase 3 study

    Interview of Angela Hildreth, FD and COO, by Proactive Investors in which she discusses the first patient in its Phase 3 clinical study of MED2005

  • MED2005 treatment clinical trial set to begin

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses MED2005

  • Phase 3 study kick off

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the lead asset MED2005

  • MED2005 Clinical Programme Update

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the first Phase 3 efficacy trial for MED2005

  • Preliminary results for the year ended 31 December 2017

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the progress across Futura's portfolio of products.

  • MED2005 interview

    Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the recent article published by the Journal of Sexual Medicine.

  • MED2005 update

    Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the start of the PK study and provides a regulatory, clinical and commercial update.

  • Positive market research data on MED2005

    Interview of James Barder, Chief Executive, by Proactive Investors in which James discusses the positive market research data on MED2005 announced on 16 October 2017.

  • Interim results

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the Interim results for the period ending 30 June 2017 including the Phase 3 programme for MED2005 and the strategy for CSD500.

  • Church and Dwight license termination

    Interview of James Barder, Chief Executive, by Proactive Investors in which he discusses the change of priorities which sees Futura Medical distributor terminate licensing agreement.

  • Critical step in the development of MED2005

    Video Interview of James Barder discussing a 'critical step' in the development of MED2005

  • Preliminary results

    Video Interview of James Barder discussing the Preliminary results for the year ended 31 December 2016

  • Significant interest for MED2005

    Video Interview of James Barder discussing the significant interest for MED2005, Futura’s erectile dysfunction gel based on Ipsos research

  • UK licensing agreement

    Video Interview of James Barder discussing the UK licensing agreement for its pain relief gel TPR100 and the launch of CSD500 in Saudi Arabia

  • Futura Medical confirm US Food & Drug Administration agreement 'hot on heels' of EU regulatory steps

    22 March 2021

    Interview with Ken James Futura Medical confirm US Food & Drug Administration agreement 'hot on heels' of EU regulatory steps